A summary of letters sent to healthcare professionals in July 2016 to inform of safety information for riociguat and for posaconazole.
In July 2016, the following letters were sent to relevant healthcare professionals:
riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. See also article in July 2016 issue of Drug Safety Update
posaconazole (Noxafil): tablets and oral suspension are not interchangeable
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.